跳至主要内容
临床试验/NL-OMON40833
NL-OMON40833尚未招募不适用

Pharmacologic Evaluation of Intravenous Haloperidol for the Treatment of Delirium in Critically Ill Adults - Pharmacologics of Haloperidol

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - adult patients (>18 years) with a diagnosis of delirium according to the ICDSC (Intensive Care Delirium Screening Checklist from day 1 of ICU treatment or later (or patients with haloperidol at day of admission, without prior treatment of haloperidol).
  • - expected ICU-stay of > 48 hours,
  • - scheduled to be treated with IV haloperidol as per the ErasmusMC ICU delirium treatment protocol

排除标准

  • - Treatment with haloperidol in the 24 hours before ICU admission
  • - ICDSC cannot be obtained due to coma
  • - end stage liver failure
  • - primary neurologic disease (if ICDSC score cannot be performed)
  • - history of severe dementia
  • - history of parkinsonism and/or psychosis
  • - a baseline QTc > 450msec at admission
  • - use of medications with known major interaction with haloperidol (i.e. bosentan, carbamazepine, efavirenz, etravirine, phenobarbital, phenytoin, nevirapine, primidon, rifabutin, lopinavir, ritonavir and rifampicin), patients with delirium caused by acute alcohol withdrawal
  • - pregnancy

研究者

相似试验